GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Innovation1 Biotech Inc (OTCPK:IVBT) » Definitions » Capex-to-Operating-Cash-Flow

Innovation1 Biotech (Innovation1 Biotech) Capex-to-Operating-Cash-Flow : 0.00 (As of Aug. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Innovation1 Biotech Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Innovation1 Biotech's Capital Expenditure for the three months ended in Aug. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Aug. 2023 was $-0.03 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Innovation1 Biotech Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Innovation1 Biotech's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation1 Biotech Capex-to-Operating-Cash-Flow Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

Innovation1 Biotech Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innovation1 Biotech's Capex-to-Operating-Cash-Flow

For the Shell Companies subindustry, Innovation1 Biotech's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovation1 Biotech's Capex-to-Operating-Cash-Flow Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Innovation1 Biotech's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Innovation1 Biotech's Capex-to-Operating-Cash-Flow falls into.



Innovation1 Biotech Capex-to-Operating-Cash-Flow Calculation

Innovation1 Biotech's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Aug. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.62
=N/A

Innovation1 Biotech's Capex-to-Operating-Cash-Flow for the quarter that ended in Aug. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.027
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovation1 Biotech  (OTCPK:IVBT) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Innovation1 Biotech Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Innovation1 Biotech's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovation1 Biotech (Innovation1 Biotech) Business Description

Traded in Other Exchanges
N/A
Address
40 Wall Street, Suite 2701, New York, NY, USA, 10005
Innovation1 Biotech Inc is a shell company.
Executives
Grays Peak Llc 10 percent owner 8 THE GREEN, STE. A, DOVER DE 19803
Timothy Orr director, 10 percent owner, officer: President 4010 TANAGER LANE, #A, MEAD WA 99021
Darren Long director, 10 percent owner, officer: CEO & Secretary 4010 TANAGER LANE, #A, MEAD WA 99021
Brian Martinho director, 10 percent owner, officer: Treasurer 4010 EAST TANAGER LANE, MEAD WA 99021